BGC vs CRSP Comparison

BGC Group Inc is a brokerage and financial technology company that serves the global financial markets, energy and commodities markets. Its service and product offerings include brokerage for a wide range of financial products including fixed income, equities, commodities, derivatives, and real estate, software solutions for trading platforms, clearing, trade execution, and other back-office services. Its clients mostly include banks, financial institutions and corporate clients. BGC operates in one reportable segment, which is providing brokerage services. Geographically the company generates revenue from Asia, Other Europe/MEA, France, Other Americas with the majority of its revenue coming from United Kingdom followed by the United States.

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.